Inovio Q2 FY26 net loss narrows to $6.01 million; operating loss improves to $18.62 million

Reuters2026/08/12 20:09

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Inovio posted a Q2 net loss of USD 6.01 million, narrowing from a USD 23.52 million loss a year earlier.
R&D expense fell 25.41% to USD 10.83 million; G&A expense declined 8.9% to USD 7.8 million.
Total operating expenses dropped 19.33% to USD 18.62 million, while operating loss narrowed to USD 18.62 million from USD 23.08 million.
Cash, cash equivalents and short-term investments totaled USD 36.7 million at June 30, down from USD 58.5 million at Dec. 31.
FDA review of the INO-3107 BLA advanced toward an Oct. 30, 2026 PDUFA date; cash runway guided into late Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inovio Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608121605PR_NEWS_USPR_____PH25150) on August 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Inovio Q2 FY26 net loss narrows to $6.01 million; operating loss improves to $18.62 million

You may also like

Crypto prices